JWJun Wang

Jun Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jun Wang has a total of 79 co-authors. Here are the top co-authors by number of shared publications:

  • Guihong Pan

    Department of Pediatric Surgery, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China

    3 shared publications
  • Jie Zhou

    Tianjin Institute of Immunology, Key Laboratory of Immune Microenvironment and Disease of the Ministry of Education, Department of Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China

    2 shared publications
  • Jun Zhang

    Precision Research Center for Refractory Diseases, State Key Laboratory of Innovative Immunotherapy Institute for Clinical Research Shanghai Key Laboratory of Pancreatic Diseases Department of Gastrointestinal Surgery Department of Gastroenterology Department of Nursing Department of Obstetrics and Gynecology Shanghai General Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200080 China

    2 shared publications
  • Xiaojiang Lai

    Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications
  • Xixi Feng

    Guangzhou Medical University-Guangzhou Institute of Biomedicine and Health (GMU-GIBH) Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, China

    2 shared publications
  • Andrew M. Lew

    The Walter & Eliza Hall Institute of Medical Research, Parkville, VIC, Australia

    1 shared publication

Latest Publications

  • Open Access

    TDP-43 promotes allergen-induced inflammation and influenza A virus replication in airway epithelium

    by Yanmei Yuan, Wenzhu Tang, Xixi Feng, Chunlei Zhang, Yingying Liao, Meiyan Tang, Jian He, Shengpeng Wan, Guihong Pan, Xiaojiang Lai, et al.

    Current targeted therapeutics for asthma focus on the T2 immune response, providing symptomatic management without addressing the issues of recurrence. Identifying key pathophysiological determinants in airway epithelium enables novel therapeutics to prevent asthma recurrence. Here we demonstrate that TDP-43, as the master regulator of RNA metabolism, is induced in airway epithelial cells by host allergen exposure and promotes asthmatic airway responses through dampening nonsense-mediated decay (NMD) by modulating UPF1 expression, resulting in accumulation of pathogenic and NMD-sensitive transcripts including CHRM1 encoding receptor that transduces the signaling of vagally-derived neurotransmitter acetylcholine. TDP-43 also facilitates airway influenza A virus replication. Intranasal application of lipid nanoparticles carrying antisense oligonucleotides targeting TDP-43 effectively reduce asthma-like pathologies in mice. Our findings indicate that targeting airway TDP-43 is therapeutically possible for asthma and influenza A virus infection-complicated asthma exacerbations.

  • Open Access

    Targeting DAP5 Disrupts Alternate Mode of Translational Initiation in Tregs and Potentiates Antitumor Immunity

    by Xiaojiang Lai, Guihong Pan, Xixi Feng, Jun Zhang, Yunxia Li, Shanmeizi Zhao, Zhenming Lin, Yun Feng, Wei Bao, Hongyan Yang, et al.

    Regulatory T cells (Tregs) can thrive in the harsh tumor microenvironment (TME) to dampen antitumor immunity. Chronic stresses within TME compromise canonical cap‐dependent translation (CDT), which compromises effector T cell function but not Treg persistence. Death‐associated protein 5 (DAP5/eIF4G2), a non‐classical translational scaffold, has been reported to support human Treg differentiation in vitro, but its functions in thymic Treg development, peripheral Treg homeostasis, and tumor‐infiltrating Treg (ti‐Treg) fitness remain unclear. Here, it is shown that DAP5 expression positively correlates with ti‐Treg frequencies in both colorectal cancer patients and murine subcutaneous tumors. Mice with homozygous Dap5 deletion in Tregs has intact thymic and peripheral Treg development but spontaneously developed typical scurfy symptoms. Haploinsufficiency of Dap5 in Tregs preserves peripheral immune homeostasis while suppressing tumor growth, with enhanced CD8 + T cell infiltration and effector function. Mechanistically, Dap5 mediates alternate mode of translation of transcripts encoding CD25 and MCL‐1 in Tregs, thereby sustaining Treg lineage stability and survival in the stressful TME. Overall, Tregs rely on DAP5‐driven alternate translation to maintain peripheral homeostasis and acquired fitness within the TME. Selective disruption of this pathway impairs ti‐Tregs while sparing systemic tolerance, offering a potential therapeutic strategy to enhance anti‐tumor immunity.


  • Open Access

    BACH2 drives the development and function of group 2 innate lymphoid cells

    by Gaoyu Liu, Ying Wang, Xianfu Yi, Jianye Wang, Jun Zhang, Xixi Feng, Haitao Wang, Chun Chen, Qiang Liu, Jun Wang, et al.

    Group 2 innate lymphoid cells (ILC2s) represent one of the major drivers of allergic inflammation; however, the precise mechanisms governing the development and function of ILC2s remain unknown. Here, we show that the transcription factor BACH2 was abundantly expressed and epigenetically activated in ILC2s and their progenitors. Conditional ablation of BACH2 diminished the ability of ILC2 progenitors to differentiate into ILC2s. Integration of the scRNA-seq, ATAC-seq, and CUT&Tag-seq techniques revealed that BACH2 modulated the transcriptional profiles and epigenetic landscapes of ILC2 progenitors. Furthermore, BACH2 ablation compromised the functionality of ILC2s, resulting in a resolution of allergic airway inflammation. Notably, the different binding sites of BACH2 in ILC2s and T H 2 cells suggested that BACH2 binds to IRF4 to control the function of ILC2, underscoring its context-specific effects on allergic airway inflammation. These findings shed promising light on the importance of BACH2 in type 2 immunity and its multifaceted role in asthma.


  • Open Access

    Single-cell transcriptomic analysis reveals heterogeneous features of myeloid-derived suppressor cells in newborns

    by Meng Yao, Yingjiao Cao, Juan He, Rui Dong, Gaoyu Liu, Yingying Chen, Jun Wang, Jie Zhou

    The transitory emergence of myeloid-derived suppressor cells (MDSCs) in infants is important for the homeostasis of the immune system in early life. The composition and functional heterogeneity of MDSCs in newborns remain elusive, hampering the understanding of the importance of MDSCs in neonates. In this study, we unraveled the maturation trajectory of polymorphonuclear (PMN)-MDSCs from the peripheral blood of human newborns by performing single-cell RNA sequencing. Results indicated that neonatal PMN-MDSCs differentiated from self-renewal progenitors, antimicrobial PMN-MDSCs, and immunosuppressive PMN-MDSCs to late PMN-MDSCs with reduced antimicrobial capacity. We also established a simple framework to distinguish these distinct stages by CD177 and CXCR2. Importantly, preterm newborns displayed a reduced abundance of classical PMN-MDSCs but increased late PMN-MDSCs, consistent with their higher susceptibility to infections and inflammation. Furthermore, newborn PMN-MDSCs were distinct from those from cancer patients, which displayed minimum expression of genes about antimicrobial capacity. This study indicates that the heterogeneity of PMN-MDSCs is associated with the maturity of human newborns.


  • Inherited KDM6AA649T facilitates tumor-immune escape and exacerbates colorectal signet-ring cell carcinoma outcomes

    by Maoxiao Feng, Chengwei Chai, Xiaodong Hao, Xiaojiang Lai, Yuanyuan Luo, Hong Zhang, Wenzhu Tang, Ningxin Gao, Guihong Pan, Xiaojie Liu, et al.

    Childhood onset of colorectal signet-ring cell carcinoma (CR-SRCC) is extremely rare and featured as highly malignant with poor prognosis. Here we reported a CR-SRCC case of 11-year-old boy with a novel inherited X-linked KDM6AA694T mutation. The H3K27me3 demethylase KDM6A was frequently mutated in varieties of tumors and acts as a tumor suppressor. In vivo H3K27me3 demethylation assay demonstrated that KDM6AA694T had dampened H3K27me3 demethylase activity. Overexpression of KDM6AA694T in SRCC cell line KATO3 promoted cell proliferation, invasion and migration, which were further confirmed in vivo by constructing orthotopic tumor growth and lung metastasis model. Besides, expression of KDM6AA694T in immune cells suppresses inflammatory macrophage response and effector T cell response. In conclusion, we characterized a novel inherited KDM6AA694T mutant from a childhood-onset SRCC case and demonstrated that the mutant with impaired H3K27me3 demethylase activity could potentiate tumor malignancy and suppress antitumor immunity.


  • Open Access

    Repairing Mechanisms for Distal Airway Injuries and Related Targeted Therapeutics for Chronic Lung Diseases

    by Huahua Xu, Guihong Pan, Jun Wang

    Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), involve progressive and irreversible destruction and pathogenic remodeling of airways and have become the leading health care burden worldwide. Pulmonary tissue has extensive capacities to launch injury-responsive repairing programs (IRRPs) to replace the damaged or dead cells upon acute lung injuries. However, the IRRPs are frequently compromised in chronic lung diseases. In this review, we aim to provide an overview of somatic stem cell subpopulations within distal airway epithelium and the underlying mechanisms mediating their self-renewal and trans-differentiation under both physiological and pathological circumstances. We also compared the differences between humans and mice on distal airway structure and stem cell composition. At last, we reviewed the current status and future directions for the development of targeted therapeutics on defective distal airway regeneration and repairment in chronic lung diseases.


  • Open Access

    Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction

    by Xiaoyan Liu, Zhe Li, Shuai Liu, Zhanghua Chen, Jing Sun, Zhiyao Zhao, Yi-You Huang, Qingling Zhang, Jun Wang, Yinyi Shi, et al.

    The human coronavirus HCoV-19 infection can cause acute respiratory distress syndrome (ARDS), hypercoagulability, hypertension, extrapulmonary multiorgan dysfunction. Effective antiviral and anti-coagulation agents with safe clinical profiles are urgently needed to improve the overall prognosis. We screened an FDA approved drug library and found that an anticoagulant agent dipyridamole (DIP) suppressed HCoV-19 replication at an EC50 of 100 nM in vitro . It also elicited potent type I interferon responses and ameliorated lung pathology in a viral pneumonia model. In analysis of twelve HCoV-19 infected patients with prophylactic anti-coagulation therapy, we found that DIP supplementation was associated with significantly increased platelet and lymphocyte counts and decreased D-dimer levels in comparison to control patients. Two weeks after initiation of DIP treatment, 3 of the 6 severe cases (60%) and all 4 of the mild cases (100%) were discharged from the hospital. One critically ill patient with extremely high levels of D-dimer and lymphopenia at the time of receiving DIP passed away. All other patients were in clinical remission. In summary, HCoV-19 infected patients could potentially benefit from DIP adjunctive therapy by reducing viral replication, suppressing hypercoagulability and enhancing immune recovery. Larger scale clinical trials of DIP are needed to validate these therapeutic effects.


  • Open Access

    Establishment of a 12-gene expression signature to predict colon cancer prognosis

    by Dalong Sun, Jing Chen, Longzi Liu, Guangxi Zhao, Pingping Dong, Bingrui Wu, Jun Wang, Ling Dong

    A robust and accurate gene expression signature is essential to assist oncologists to determine which subset of patients at similar Tumor-Lymph Node-Metastasis (TNM) stage has high recurrence risk and could benefit from adjuvant therapies. Here we applied a two-step supervised machine-learning method and established a 12-gene expression signature to precisely predict colon adenocarcinoma (COAD) prognosis by using COAD RNA-seq transcriptome data from The Cancer Genome Atlas (TCGA). The predictive performance of the 12-gene signature was validated with two independent gene expression microarray datasets:GSE39582includes 566 COAD cases for the development of six molecular subtypes with distinct clinical, molecular and survival characteristics;GSE17538is a dataset containing 232 colon cancer patients for the generation of a metastasis gene expression profile to predict recurrence and death in COAD patients. The signature could effectively separate the poor prognosis patients from good prognosis group (disease specific survival (DSS): Kaplan Meier (KM) Log Rankp= 0.0034; overall survival (OS): KM Log Rankp= 0.0336) inGSE17538. For patients with proficient mismatch repair system (pMMR) inGSE39582, the signature could also effectively distinguish high risk group from low risk group (OS: KM Log Rankp= 0.005; Relapse free survival (RFS): KM Log Rankp= 0.022). Interestingly, advanced stage patients were significantly enriched in high 12-gene score group (Fisher’s exact testp= 0.0003). After stage stratification, the signature could still distinguish poor prognosis patients inGSE17538from good prognosis within stage II (Log Rankp = 0.01) and stage II & III (Log Rankp= 0.017) in the outcome of DFS. Within stage III or II/III pMMR patients treated with Adjuvant Chemotherapies (ACT) and patients with higher 12-gene score showed poorer prognosis (III, OS: KM Log Rankp= 0.046; III & II, OS: KM Log Rankp= 0.041). Among stage II/III pMMR patients with lower 12-gene scores inGSE39582, the subgroup receiving ACT showed significantly longer OS time compared with those who received no ACT (Log Rankp= 0.021), while there is no obvious difference between counterparts among patients with higher 12-gene scores (Log Rankp= 0.12). Besides COAD, our 12-gene signature is multifunctional in several other cancer types including kidney cancer, lung cancer, uveal and skin melanoma, brain cancer, and pancreatic cancer. Functional classification showed that seven of the twelve genes are involved in immune system function and regulation, so our 12-gene signature could potentially be used to guide decisions about adjuvant therapy for patients with stage II/III and pMMR COAD.